Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

ClostraBio, a biotechnology company developing next-generation probiotics to support gut health, today announced the full ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing ...

US Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed in public statements that most vaccines recommended for children in the US have not been tested against placebos, ...

Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...

MRM Health receives US FDA IND clearance to initiate phase 2b trial of MH002 in mild-to-moderate ulcerative colitis: Ghent, Belgium Saturday, January 10, 2026, 16:00 Hrs [IST] MRM ...

Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized to receive either ACOU085 or placebo administered prior to each cisplatin ...